1. Home
  2. RRR vs BLLN Comparison

RRR vs BLLN Comparison

Compare RRR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Rock Resorts Inc.

RRR

Red Rock Resorts Inc.

HOLD

Current Price

$61.27

Market Cap

3.4B

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$103.91

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RRR
BLLN
Founded
1976
2016
Country
United States
United States
Employees
N/A
713
Industry
Hotels/Resorts
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.9B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
RRR
BLLN
Price
$61.27
$103.91
Analyst Decision
Strong Buy
Buy
Analyst Count
13
7
Target Price
$69.69
$126.71
AVG Volume (30 Days)
776.8K
708.8K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.64%
N/A
EPS Growth
23.32
N/A
EPS
0.73
N/A
Revenue
$2,011,483,000.00
N/A
Revenue This Year
$3.41
$46.29
Revenue Next Year
$4.62
$30.14
P/E Ratio
$81.01
N/A
Revenue Growth
3.74
N/A
52 Week Low
$50.03
$61.96
52 Week High
$68.99
$138.70

Technical Indicators

Market Signals
Indicator
RRR
BLLN
Relative Strength Index (RSI) 61.17 59.06
Support Level $59.80 $79.07
Resistance Level $63.34 $108.50
Average True Range (ATR) 1.83 7.70
MACD 0.16 0.14
Stochastic Oscillator 67.76 72.62

Price Performance

Historical Comparison
RRR
BLLN

About RRR Red Rock Resorts Inc.

Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: